
Induction Healthcare Group
Leading healthcare technology company helping healthcare professionals deliver better care more efficiently.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
N/A | €0.0 | round | |
investor | €0.0 | round | |
* | £9.7m Valuation: £9.7m 0.7x EV/Revenue -58.8x EV/EBITDA | Acquisition | |
Total Funding | 000k |
GBP | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | - | - | 922 % | 423 % | 63 % | 6 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | - | (2197 %) | (351 %) | (72 %) | (97 %) | (1 %) |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | - | (2383 %) | (503 %) | (107 %) | (135 %) | (24 %) |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | - | 650 % | 125 % | 76 % | 72 % | 64 % |
Source: Company filings or news article
Related Content
Induction Healthcare Group PLC, listed on the AIM market of the London Stock Exchange, operates as a specialized digital health company focused on streamlining care delivery for healthcare professionals and patients. The company was co-founded in 2015 by Ibs Mahmood and Hugo Stephenson. Mahmood, with a background in neurosurgery and experience in NHS England's innovation team, and Stephenson, a medically qualified doctor with a history of building and selling health-tech companies, established the firm to address communication inefficiencies within healthcare systems.
The group's core business revolves around providing software-as-a-service (SaaS) solutions to public and private healthcare organizations, primarily targeting the UK's National Health Service (NHS). Its revenue model is based on recurring subscription fees for its suite of products. A significant milestone in the company's history was the acquisition of Zesty in 2020, a platform for patient engagement with hospitals, and a subsequent reverse takeover of the AIM-listed cash shell Sensyne Health plc in 2022, which significantly expanded its market presence and product offering. More recently, in a strategic shift announced in late 2023 and completed in early 2024, Induction sold its Attend Anywhere and GoodSAM assets to the Australian company Coviu Global Pty Ltd. This move refocused the business on its core products: Induction Zesty and Induction Switch.
The Induction Zesty platform is a patient portal that integrates with hospital Electronic Patient Record (EPR) systems. It allows patients to manage their outpatient appointments, view hospital letters digitally, and access their clinical records. This service aims to reduce administrative burdens for hospitals and improve the patient experience. The other key product, Induction Switch, is a widely used application among UK clinical staff. It functions as a secure communication and collaboration tool, enabling healthcare professionals to connect with the right person or department quickly and efficiently, thereby saving time and improving care coordination. The platform's extensive directory is a key feature, making it a practical tool for daily use by clinicians within the NHS.
Keywords: digital health, healthcare SaaS, patient engagement, clinical communication, NHS supplier, health-tech, patient portal, clinical collaboration, hospital administration, UK healthcare
Tech stack
Investments by Induction Healthcare Group
Edit

